Effect of rimonabant on oesophageal motor function in man

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2011, Pages 730-737

  Scarpellini, E ^a   Blondeau, K ^a   Boecxstaens, V ^a   Vos, R ^a   Gasbarrini, A ^a   Farre R ^a   Tack, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HALF LIFE; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS PH; FEMALE; HUMAN; HUMAN EXPERIMENT; LOWER ESOPHAGUS SPHINCTER; MALE; NORMAL HUMAN; PERISTALSIS; POSTPRANDIAL STATE; PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE RELAXATION; VOLUNTEER;

ADULT; EPIDEMIOLOGIC METHODS; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGUS; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MUSCLE RELAXATION; PIPERIDINES; POSTPRANDIAL PERIOD; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 79951677191     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04576.x     Document Type: Article

References (49)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R,; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. Tack J,. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and non-erosive reflux disease. Curr Opin Gastroenterol 2005; 21: 454-60. (Pubitemid 40961174)
3. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J,. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barretts oesophagus. Gut 2008; 57: 1056-64.
4. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent symptomatic subjects. J Clin Invest 1980; 65: 256-67. (Pubitemid 10159855)
5. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982; 307: 1547-52. (Pubitemid 13245429)
6. Dent J, Holloway RH, Toouli J, Dodds WJ,. Mechanisms of lower esophageal sphincter incompetence in patients with symptomatic gastroesophageal reflux. Gut 1988; 29: 1020-8.
7. Mittal RK, McCallum RW,. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988; 95: 593-9.
8. Achem SR, Robinson M,. A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998; 16: 38-46. (Pubitemid 128527700)
9. Blackshaw LA, Staunton E, Lehmann A, Dent J,. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999; 277: G867-74. (Pubitemid 29525939)
10. Lehmann A, Antonsson M, Bremner-Danielsen M, FlaÂrdh M, Hansson-Branden J, Kärrberg L,. Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in the dog. Gastroenterology 1999; 117: 1147-54. (Pubitemid 29512674)
11. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH,. Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13. (Pubitemid 30020367)
12. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH,. Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastroesophageal reflux disease. Gut 2002; 50: 19-24. (Pubitemid 34028297)
13. Van Herwaarden MA, Samsom M, Rydholm H, Smout AJPM,. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002; 16: 1655-62.
14. Lee KJ, Vos R, Janssens J, Tack J,. Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans. Aliment Pharmacol Ther 2003; 18: 199-207. (Pubitemid 36951656)
15. Partosoedarso ER, Young RL, Blackshaw LA,. GABA(B) receptors on vagal afferent pathways: peripheral and central inhibition. Am J Physiol 2001; 280: G658-68.
16. Bowery NG, Enna SJ,. Gamma-Aminobutyric acid B receptors: first of the functional metabotropic heterodimers. J Pharmacol Exp Ther 2000; 292: 2-7. (Pubitemid 30026349)
17. Pertwee RG,. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80. (Pubitemid 27337346)
18. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-7. (Pubitemid 30143137)
19. Simoneau II, Hamza MS, Mata HP, et al. The cannabinoid agonist WIN55,212-2 suppresses opiod-induced emesis in ferrets. Anesthesiology 2001; 94: 882-7. (Pubitemid 32429761)
20. Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121: 767-74. (Pubitemid 32959386)
21. Van Diepen H, Schlicker E, Michel MC,. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 345-69.
22. Hornby P,. Central neurocircuitry associated with emesis. Am J Med 2001; 111: 106S-12S. (Pubitemid 34032001)
23. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J,. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109: 601-10.
24. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
25. Diana MA, Levenes C, Mackie K, Marty A,. Short-term retrogradeinhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci 2002; 22: 200-8. (Pubitemid 34033498)
26. Wilson RI, Nicoll RA,. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-92. (Pubitemid 32267203)
27. Currioni C, Andre C,. Rimonabant for overweight or obesity. Cochrane database of systematic reviews 2006; 4: CD006162.
28. Akbas F, Gasteyger C, Larsen M, et al. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 2008; 10: 58-67.
29. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G,. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009; 156: 153-62.
30. Lehmann A, Blackshaw LA, Brändén L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002; 123: 1129-34.
31. Henness S, Robinson DM, Lyseng-Williamson KA,. Rimonabant. Drugs 2006; 66: 2109-19. (Pubitemid 46372361)
32. Scarpellini E, Vos R, Blondeau K, et al. Effect of itopride one esophageal motitiy and lower esophageal sphincter function in man. Aliment Pharmacol Ther 2011; 33: 99-105.
33. Holloway RH, Penagini R, Ireland AC,. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268: G128-33.
34. Meschler JP, Kraichely DM, Wilken GH, Howlett AC,. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4- methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano- 5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem Pharmacol 2000; 60: 1315-23.
35. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG,. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613-23. (Pubitemid 46355558)
36. Tack J, Sifrim D,. Anti-relaxation therapy in GORD. Gut 2002; 50: 6-7. (Pubitemid 34028292)
37. Tack J,. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease. Curr Opin Gastroenterol 2005; 21: 454-60. (Pubitemid 40961174)
38. Boeckxstaens GE,. Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 2008; 8: 685-9.
39. Pertwee RG,. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-67. (Pubitemid 32476991)
40. Duncan M, Davison JS, Sharkey KA,. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005; 22: 667-83. (Pubitemid 41475329)
41. Hornby PJ, Prouty SM,. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004; 141: 1335-45. (Pubitemid 38638823)
42. Boesmans W, Ameloot K, van den Abbeel V, Tack J, Vanden Berghe P,. Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil 2009; 21: 958-e77.
43. Ameloot K, Janssen P, Scarpellini E, et al. Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther 2010; 31: 1123-31.
44. Keywood C, Wakefield M, Tack J,. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009; 58: 1192-9.
45. Zerbib F, Keywood C, Strabach G,. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol Motil 2010; 22: 859-65.
46. Blondeau K,. Treatment of gastro-esophageal reflux disease: the new kids to block. Neurogastroenterol Motil 2010; 22: 836-40.
47. Moreira FA, Grieb M, Lutz B,. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009; 23: 133-44.
48. Pavó FJ, Serrano A, Pérez-Valero V, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 2008; 20 (Suppl. 1): 116-23. (Pubitemid 351552685)
49. Gõmez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-7. (Pubitemid 35356203)